Cytecare Hospitals has now forayed into providing dedicated cancer care with its first organ site focused 150-bed facility in Bengaluru. The six storied facility in Yelankha enroute to Bengaluru’s Kempegowda International Airport is the flagship facility of the healthcare major’s 4- 5 similar hubs which are planned across India.
The hospital utilizes Digital Breast Tomosynthesis (DBT), a next-generation breast imaging digital technology. It is also the first hospital in Karnataka to have the Elekta Versa HD. Globally, the advanced linear accelerator is used in the delivery of stereotactic body radiotherapy (SBRT) and radiosurgery (SRS). The high precision Versa HD provides the industry’s largest IGRT cone-beam CT field-of-view and designed with patient safety in mind. The customised hospital building is equipped with five major operating theatres, radiology and nuclear medicine suite and advanced.
“Our primary attention is on the Indian patients and of course international cases will also be attended to. Leading oncologists and medical professionals from the best centres in the country and globally have partnered in this mission. We will provide the much-needed advances not just in treatment but diagnostics and drugs. The objective is to drive medical excellence, global best practices to deliver superior clinical outcomes”, Dr. Ferzaan Engineer, co-founder & chairman of Cytecare told Pharmabiz prior to the inauguration.
The Rs.165 crore equity funded facility, is armed with a team of organ-site oncologists and medical specialists along with the best equipment available globally to ensure that every patient is treated in the right way. We are being supervised by a multi-disciplinary Tumour Board, he added.
“Cancer treatment is evolving every day and newer techniques and treatment protocols are being developed to increase the probability of positive outcomes. Medical research has revealed that no two cancer patients are identical and hence each person needs a customized treatment protocol. Therefore, we have invested in advanced diagnostic and therapeutic modalities,” said Dr. Engineer who was earlier CEO, Quintiles Research (India) and a member of the Asia-Pacific Management Board of Quintiles.
Our effort is ensure continuity of care. This would see us expand across 4-5 major hospitals in the country via a hub-and-spoke model with sub-centres to strengthen the network for easy access to patients. The network also plans various outreach initiatives to engage communities for better health., noted Suresh Ramu, co-founder & CEO of Cytecare and also an erstwhile Quintiles India Clinical Development team lead member.
“Treatment of cancer depends on several factors, including patient profile, family medical history, responsiveness to various treatments and the clinical support to overcome this challenging disease. The hospital will empower patients with information and counselling. It will also focus nursing, pain and palliation, physiotherapy and nutrition. We will also go the extra mile to ensure a patient’s comfort by providing holistic care and a tranquil environment”, stated the Cytecare CEO.